Preclinical Results of Camptothecin-Polymer Conjugate (IT-101) in Multiple Human Lymphoma Xenograft Models

Tontanai Numbenjapon,1 Jianyi Wang,1 David Colcher,1 Thomas Schluep,4 Mark E. Davis,5 Julienne Duringer,4 Leo Kretzner,2 Yun Yen,2 Stephen J. Forman,3 and Andrew Raubitschek1

Abstract

Purpose: Camptothecin (CPT) has potent broad-spectrum antitumor activity by inhibiting type I DNA topoisomerase (DNA topo I). It has not been used clinically because it is water-insoluble and highly toxic. As a result, irinotecan (CPT-11), a water-soluble analogue of CPT, has been developed and used as salvage chemotherapy in patients with relapsed/refractory lymphoma, but with only modest activity. Recently, we have developed a cyclodextrin-based polymer conjugate of 20-(S)-CPT (IT-101). In this study, we evaluated the preclinical antilymphoma efficacy of IT-101 as compared with CPT-11.

Experimental Design: We determined an in vitro cytotoxicity of IT-101, CPT-11, and their metabolites against multiple human lymphoma cell lines. In human lymphoma xenografts, the pharmacokinetics, inhibitions of tumor DNA topo I catalytic activity, and antilymphoma activities of these compounds were evaluated.

Results: IT-101 and CPT had very high in vitro cytotoxicity against all lymphoma cell lines tested. As compared with CPT-11 and SN-38, IT-101 and CPT had longer release kinetics and significantly inhibit higher tumor DNA topo I catalytic activities. Furthermore, IT-101 showed significantly prolonged the survival of animals bearing s.c. and disseminated human xenografts when compared with CPT-11 at its maximum tolerated dose in mice.

Conclusions: The promising present results provide the basis for a phase I clinical trial in patients with relapsed/refractory lymphoma.

Although great advances have been made in the treatment of malignant lymphoma, more than half of the patients with aggressive non-Hodgkin lymphoma and a vast majority of patients with indolent lymphoma have resistant diseases or relapse after the initial treatment and eventually require salvage chemotherapy. In general, patients with Burkitt lymphoma, anaplastic large T-cell lymphoma, and advanced-stage Hodgkin lymphoma who receive first-line combination chemotherapies can achieve 5-year overall survival rate of 65% to 90%, 37% to 93%, and 66% to 82% of patients, respectively (1–5). However, only a small number of these patients can achieve long-term disease-free survival after high-dose therapy and hematopoietic stem cell rescue. The limitation of this approach is that not all patients respond to widely used salvage therapies including EP-OCH (6), ESHAP (7), and MINE-ESHAP (8). Therefore, a novel agent for the salvage setting in these patients is needed. The development of salvage regimens is based on the combination of non-cross-resistant agents from the first-line chemotherapy regimens. The DNA topoisomerase I (Topo I) inhibitors have been explored as candidates for salvage therapy in patients with relapsed/refractory non-Hodgkin lymphoma due to an increase in DNA Topo I activity in lymphoma cells. 20(S)-Camptothecin (CPT) is a plant alkaloid present in fruit, bark, and wood of the Camptotheca acuminata. CPT has a broad spectrum of antitumor activity that mediates through interaction with the nuclear enzyme Topo I and prevents it from resolving the DNA break, resulting in a double-strand DNA break and cell death (9–12). Moreover, it is a poor substrate for P-glycoprotein, a class of drug efflux pumps that is up-regulated in many multidrug resistant cancer cells. However, the clinical use of CPT has been precluded by its significant treatment-related toxicity (TRT) and low antitumor efficacy (13, 14). Irinotecan (CPT-11), an analogue of CPT, has been used alone or in combination with other cytotoxic agents as salvage regimen for patients with relapsed/refractory non-Hodgkin lymphoma (15–18). In spite

References

1. Cancer Immunotherapeutics and Tumor Immunology, Beckman Research Institute at City of Hope. 2Translational Research Laboratory, Clinical and Molecular Pharmacology, and 3Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte, California; and 4Insert Therapeutics Inc., and 5Chemical Engineering, California Institute of Technology, Pasadena, California. Received 11/27/08; revised 2/18/09; accepted 2/21/09; published OnlineFirst 6/23/09.

Grant support: City of Hope Lymphoma SPORE Grant (P50 CA107399).

Note: Specific Contributions: T. Numbenjapon, J. Wang, D. Colcher, T. Schluep, M.E. Davis, L. Kretzner, Y. Yen, S.J. Forman, and A. Raubitschek designed the research; T. Numbenjapon, J. Wang, J. Düringer, and L. Kretzner performed research; T. Schluep provided vital reagent; M.E. Davis developed vital reagent; T. Numbenjapon, J. Wang, D. Colcher, L. Kretzner, and S.J. Forman wrote the manuscript.

Requests for reprints: Stephen J. Forman, Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte, CA. Phone: 626-256-4673; Fax: 626-301-8256; E-mail: sforman@coh.org.

© 2009 American Association for Cancer Research. doi:10.1158/1078-0432.CCR-08-2619

4365 Clin Cancer Res 2009;15(13) July 1, 2009 www.aacrjournals.org

Downloaded from clinicapheresis.aacrjournals.org on April 13, 2017. © 2009 American Association for Cancer Research.
of the high response shown in the phase II study of CPT-11 against a broad range of solid tumors, it usually has not been employed in the treatment of malignant lymphoma. This is mainly because of its common TRT including grade 3/4 leukopenia and grade 3/4 diarrhea caused by the recommended dosing schedule of this agent (16–19). Although prolonged i.v. infusion of CPT-11 has been reported to enhance antitumor activity (20, 21), a disadvantage of this delivery method observed in xenograft models and early clinical trials was again a high incidence of TRT including diarrhea, nausea/vomiting, neutropenia, anemia, and pulmonary toxicity (22–25). IT-101, a nanoparticulate conjugate of 20(S)-camptothecin and a β-cyclodextrin-based polymer, has recently been developed to improve biodistribution to tumor tissue, minimize TRT, and increase antitumor activity (26, 27). In a preclinical study, IT-101 has been able to show antitumor activity against a broad range of solid tumors (28). Therefore, we carried out this study to determine the preclinical efficacy of this novel compound in human lymphoma xenografts.

**Materials and Methods**

**DNA construct.** The bifunctional ffLuc-Zeocon fusion gene that coexpresses the firefly luciferase (ffLuc) and zeocin (Zeo) resistance genes was cloned into pcDNA3.1+ (Invitrogen) to generate plasmid ffLuc:Zeocon-pcDNA3.1+ as previously described (29).

**Cell culture and genetic modification.** Daudi cell (human Burkitt lymphoma line) was obtained from the American Type Culture Collection. Karpas 299 cell (human anaplastic large T-cell lymphoma line) was obtained from Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH. L540 cell (human Hodgkin lymphoma line) was kindly provided by Dr. Andreas Engert (University Clinic of Cologne, Cologne, Germany). These cell lines were maintained in sterile culture media as previously described (29). Daudi and Karpas cells (8 × 10⁶) were genetically modified with 10 μg of ffLuc:Zeocon-pcDNA3.1+ linearized DNA plasmid as previously described (29). Beginning on the third day after electrottransfer, zeocin (InvivoGen) was added to the culture at a concentration of 0.1 to 0.4 mg/mL to maintain stable transfection.

**In vitro cytotoxicity of IT-101 against human lymphoma cell lines.** The toxicities of CPT, IT-101, SN-38 (active metabolite of CPT-11), and CPT-11 were determined in Daudi, Karpas 299, and L540 cells after 72 h of incubation in RPMI 1640 supplemented with 10% heat-inactivated fetal bovine serum (Daudi cell and Karpas cell) or 20% fetal bovine serum (L540 cell) using the MTS assay.

**Human lymphoma xenograft models.** Mouse care and experimental procedures were carried out in accordance with the Research Animal Care Committee (RACC) of Beckman Research Institute at City of Hope. We first established three localized s.c. models in 6- to 8-week-old female severe combined immunodeficiency (SCID/NCr, BALB/C background) mice (National Cancer Institute). These animals were injected with 0.2 mL of 1:1 mixture of tumor cell suspension in 1% human serum albumin in HBSS (Mediatech) and Matrigel (BD Biosciences) into their right flanks. The cell dose of Daudi cell, Karpas 299 cell, and L540 cell was 5 × 10⁶, 3 × 10⁶, and 5 × 10⁶ cells, respectively. To establish two disseminated models, 6- to 8-week-old female nonobese diabetic severe combined immunodeficiency (NOD.scid/NCr) mice (National Cancer Institute) were injected with 0.2 mL of 1:1 lymphoma cells stably expressing ffLuc activity in a suspension of 1× Dulbecco’s PBS solution (Mediatech) and 1% heat-inactivated fetal bovine serum via lateral tail vein. The cell doses of Daudi cell and Karpas 299 cell were 7.5 × 10⁶ and 5 × 10⁶ cells, respectively.

**Plasma and tumor concentrations of IT-101, CPT-11, and SN-38.** Localized s.c. human xenograft-bearing animals with tumor volumes reaching approximately 500 to 800 mm³ were randomly divided into two treatment groups of 20 animals each: group 1 on CPT-11 (100 mg/kg, i.p., single dose) and group 2 on IT-101 (10 mg/kg, i.v., single dose). Then tumor specimens and plasma from five mice in each treatment group were corrected at four time points (before dosing, and 2, 24, and 48 h after dosing) to measure plasma and tumor concentrations of the compounds and their active metabolites. Measurements of plasma and tumor concentrations of IT-101 and CPT were carried out for SCID mice treated with IT-101, whereas those of CPT-11 and SN-38 were carried out for mice treated with CPT-11. The method of these measurements has been previously described (26).

**Tumor type I DNA Topo I catalytic activity inhibited by IT-101 and CPT-11.** At each time point along with the measurements of plasma and tumor concentrations of IT-101, CPT-11, and their metabolites, the inhibition of tumor DNA Topo I catalytic activity after administration of either IT-101 or CPT-11 was evaluated. The catalytic activity of DNA Topo I was determined by measuring the relaxation of supercoiled (form I) plasmid substrate DNA using the Topo I assay kit (Topogen) essentially according to the method of Liu and Miller (30). First, preparation of crude extracts from tumor tissues was done as previously described (31). Second, nuclear extraction was done using celllytic nuclear extraction kit (Sigma-Aldrich). Then tumor DNA Topo I catalytic activity was determined following the instructions accompanying the Topo I assay kit. Briefly, the reaction mixtures used consisted of supercoiled (form I) plasmid substrate DNA (0.5 μg), tumor nuclear extract (0.5 μg total protein), and the assay buffer. Supercoiled (form I) plasmid DNA (0.5 μg) and relaxed DNA (0.5 μg) provided by the Topo I assay kit were used as the control markers. The reaction mixtures were incubated at 37°C for 30 min, and terminated by adding 5 μL stop buffer/gel loading buffer. Samples were loaded onto a 1% agarose gel submersed in 1× Tris-acetate-EDTA (TAE) buffer (50× TAE buffer: 242 g Tris base, 57.1 mL glacial acetic acid, and 100 mL 0.5 mol/L EDTA) and electrophoresed overnight at room temperature. The gel was stained with 0.2 μg/mL ethidium bromide for 20 min at...
room temperature, destained in water for 20 min, and imaged under UV light. The background of supercoiled DNA band was subtracted, and the density of the supercoiled DNA band from treated tumor divided by the density of supercoiled DNA band from untreated control and timed by 100.

**Tumor burden monitoring.** In the s.c. model, detection of tumor growth by serial physical measurements was initiated 2 to 7 d after tumor implant and repeated at least twice a week until the average tumor volume was approximately 100 to 200 mm³ at which the therapy was initiated. This was repeated at least once a week until the end of the study. The tumor volume was calculated as previously described (28). In disseminated model, in vivo biophotonic imaging (see below) was initiated approximately 7 d after tumor injection.

**Biophotonic imaging.** The in vivo flLuc-derived bioluminescent imaging (BLI) signal was evaluated using an IVIS 100 imaging system (Xenogen) at 18 min after a single i.p. injection of dissolved D-Luciferin (Xenogen) at a dose of 50 mg/kg (0.1 ml of a 10 mg/ml solution per 20-g mouse). Photons were quantified using the Living Image version 2.5 software (Xenogen). Background bioluminescence signal was defined as <10⁶ p/s/cm²/sr based on the average flLuc-derived BLI of normal control mice.

**Determination of treatment efficacy.** The treatment result for each animal may be pathologic complete tumor response, complete tumor response, or partial tumor response. In a complete tumor response, the tumor volume is <13.5 mm³ for two consecutive measurements in localized s.c. model, whereas the BLI is <10⁶ p/s/cm²/sr for two consecutive measurements in the disseminated model. A pathologic complete tumor response is defined as complete tumor response combined with evidence of nonviable tumor on histopathologic study. In a partial tumor response, the tumor volume is <50% of its pretreatment volume for two consecutive measurements and the tumor volume ≥13.5 mm³ for one or more of these two measurements, whereas the BLI is <50% of its pretreatment signal and the BLI signal >10⁶ p/s/cm²/sr for one or both of these two measurements. In accordance with the institutional RACC, the predetermined tumor end point is defined as follows: (a) tumor volume >2,000 mm³ and/or ulcerated tumor in localized s.c. model; and (b) BLI signal >10¹⁰ p/s/cm²/sr and/or weight loss >20% with evidence of progressive disease and/or hind limb paralysis and/or death from tumor progression in disseminated model. Percent animal survival is defined by the percentage of animals that did not die of the tumor or TRT or reach the predetermined tumor end point during the course of the study. At the end of the study, all survived animals were euthanized with CO₂. In order to detect some residual tumors by histopathologic study, a whole thickness of skin around the tumor injection site with or without gross tumor was harvested from animals with s.c. xenografts; whereas a brain, a heart, a spleen, a liver, ovaries, kidneys, lungs, femurs, and spines were harvested from animals with disseminated xenografts.

**Treatment schedule and tumor burden monitoring.** For reference purposes, CPT-11 was used as the internal positive control in the current study as previously described (28). Mice with established human lymphoma xenografts were allocated into five different treatment groups of nine animals each, as follows: group 1 (untreated control); group 2 (CPT-11 at 100 mg/kg, i.p., qwk × 3); group 3 (IT-101 at 5 mg/kg, i.v., qwk × 3); group 4 (IT-101 at 10 mg/kg, i.v., qwk × 3); and group 5 (single dose of IT-101 at 15 mg/kg, i.v.).

<table>
<thead>
<tr>
<th>Lymphoma cell line</th>
<th>CPT (μmol/L)</th>
<th>IT-101 (μmol/L)</th>
<th>SN-38 (μmol/L)</th>
<th>CPT-11 (μmol/L)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Daudi</td>
<td>0.06</td>
<td>0.17</td>
<td>0.003</td>
<td>62</td>
</tr>
<tr>
<td>Karpas 299</td>
<td>0.02</td>
<td>0.4</td>
<td>0.008</td>
<td>11</td>
</tr>
<tr>
<td>L540</td>
<td>0.01</td>
<td>0.06</td>
<td>0.008</td>
<td>2</td>
</tr>
</tbody>
</table>
Tumor burdens were monitored at least once weekly toward the predetermined end points or for 126 d postadministration in the localized s.c. models and for 90 d postadministration in the disseminated models.

**Tolerability.** Mice were weighed twice weekly during treatment and then weekly until the end of the study and were observed for some expected TRT, including progressive weight loss, anorexia, and diarrhea. The unacceptable TRT for the maximum tolerated dose (MTD) was defined as previously described (28).

**Statistical and graphical analyses.** For DNA Topo I catalytic activity, samples were compared by paired t-test. The survival curves were constructed using the Kaplan-Meier method. The log-rank test was used to compare the percent animal survival between treatment groups. $P < 0.05$ was considered statistically significant.

**Results**

**In vitro cytotoxicity of Topo I inhibitors against three lymphoma cell lines.** Based on the Developmental Therapeutics Program of the National Cancer Institute/NII and our unpublished data, the IC$_{50}$ of CPT, IT-101, SN-38, and CPT-11 for colon, breast, and prostate cancer cell lines were 0.02 to 0.2 μmol/L, 0.22 to 0.38 μmol/L, 0.001 to 0.003 μmol/L, and 13 to 45 μmol/L, respectively. Using MTS assay, the IC$_{50}$ ranged from 0.01 to 0.06 μmol/L and 0.06 to 0.4 μmol/L after 72 hours of incubation with CPT and IT-101, respectively, indicating that both CPT and IT-101 had very high in vitro cytotoxicity against all lymphoma cell lines tested (Table 1).

**Longer release kinetics of IT-101 and CPT as compared with CPT-11 and SN-38.** In plasma, the maximum concentration of polymer-bound CPT, free CPT, CPT-11, and SN-38 was at 2 hours posttreatment in all s.c. tumor xenograft animals tested, but the concentration of CPT-11 and SN-38 declined rapidly at 24 hours posttreatment (Fig. 1A). In the s.c. tumor xenografts themselves, the maximum concentration of polymer-bound CPT and free CPT was at 48, 24, and 48 hours posttreatment in Daudi, Karpas 299, and L540 tumors, respectively, whereas the maximum concentration of SN-38 was at 2, 2, and 24 hours posttreatment in Daudi tumors, Karpas 299 tumors, and L540 tumors, respectively (Fig. 1B). These results indicated that IT-101 has longer release kinetics in tumor than that of CPT-11.

**Tumor type I DNA Topoisomerase catalytic activity inhibited by IT-101 and CPT-11.** Based on the IT-101 kinetic data above, we predicted that IT-101 would be able to inhibit tumor DNA Topo I catalytic activity for a longer time than CPT-11. The sensitivity of tumor cells to either IT-101 or CPT-11 was determined by inhibition of tumor nuclear Topo I catalytic activity using a DNA relaxation assay. At 2, 24, and 48 hours posttreatment, both IT-101 (10 mg/kg, i.v., × 1) and CPT-11 (100 mg/kg, i.p., × 1) could significantly inhibit nuclear DNA Topo I catalytic activity in all types of s.c. lymphoma xenografts tested. At the 48-h time point, however, IT-101 could inhibit nuclear DNA Topo I catalytic activity significantly better than CPT-11 in s.c. Daudi tumors and s.c. Karpas 299 tumors ($P = 0.007$; 95% confidence interval, 11.2-30.99 and $P = 0.037$; 95% confidence interval, 2.98-48.08, respectively); although there was only a nonsignificant trend in s.c. L540 tumors ($P = 0.07$). These observations are associated with longer release kinetics of IT-101 in tumor and are consistent with the maximum concentration of polymer-bound CPT and free CPT at 48 hours posttreatment as compared with SN-38 at 2 hours posttreatment (Fig. 2).

**Tolerability.** Recent studies have shown that at the same cumulative dose, IT-101 qwk × 3 can simultaneously maximize antitumor effect and minimize TRT when compared with multiple daily dosing schedules (28). The MTD of IT-101 in solid tumor bearing athymic nude mice (no data in SCID and NOD.scid/NCr mice) was more than 16.1 mg/kg qwk × 3 but <25 mg/kg qwk × 3. However, based on our internal study of human lymphoma xenografts in athymic nude mice, the MTD of IT-101 was <15 mg/kg qwk × 2 so that three weekly doses of IT-101 at 5 mg/kg (CPT equivalents), three weekly doses of IT-101 at 10 mg/kg (CPT equivalents), and a single dose of IT-101 at 15 mg/kg (CPT equivalents) were planned for use in the present study. Except for three treatment-related deaths in SCID mice treated with IT-101 (15 mg/kg, i.v., × 1), all animals tolerated the treatments well. Treatments with three weekly doses of IT-101 at 5 mg/kg and 10 mg/kg were well tolerated in all animals. Thus, the MTD of i.v. IT-101 in tumor-bearing SCID mice was between 10 mg/kg qwk × 3 and 15 mg/kg single dose. As a result, we dropped the IT-101 (15 mg/kg, i.v., × 1) arm from the disseminated models using NOD.scid/NCr mice. Therapy with i.p. CPT-11 was generally well tolerated in both strains of animal. Mean body weight loss of SCID mice and NOD.scid/NCr mice was minimal.

**In vivo efficacy of IT-101 against localized s.c. human lymphoma xenograft models.** In localized s.c. Daudi tumors, therapy was...
initiated 10 days after tumor cell inoculation. Forty-five SCID mice with established localized s.c. tumor were allocated into five different treatment groups of nine animals per group as described earlier. The average tumor volume among all groups was equally distributed. All untreated controls and animals treated with CPT-11 developed progressive tumor growth with an average tumor volume of >2,000 mm³ within 38 days and 59 days after tumor injection, respectively. In contrast, IT-101 (5 mg/kg, i.v., qwk × 3) and IT-101 (10 mg/kg, i.v., qwk × 3) could significantly prolong the survival of the animals as compared with those treated with CPT-11 (P < 0.0001 and P < 0.0001, respectively; Fig. 3A). Five of nine mice (56%) treated with IT-101 5 mg/kg and seven of nine mice (78%) treated with IT-101 (10 mg/kg, i.v., qwk × 3) survived and were pathologically confirmed disease-free after 126 days posttreatment.

In s.c. Karpas 299 tumors, therapy was initiated four days after tumor cell inoculation. All untreated control mice developed progressive tumor growth with an average tumor volume of >2,000 mm³ within 25 days after tumor injection. As shown in Fig. 3B, although the significant difference between the groups treated with either IT-101 (5 mg/kg, i.v., qwk × 3) or IT-101 (10 mg/kg, i.v., qwk × 3) was not observed, the animals treated with IT-101 (10 mg/kg, i.v., qwk × 3) had significantly longer survival than those treated with CPT-11 (P = 0.0072). At the end of the study, 44% of animals treated with IT-101 (10 mg/kg, i.v., qwk × 3), 33% of animals treated with IT-101 (5 mg/kg, i.v., qwk × 3), and 33% of animals treated with CPT-11 achieved a pathologically confirmed disease-free status.

The antilymphoma activity of IT-101 was also evaluated in s.c. L540 tumors. In this model, therapy was initiated 16 days after tumor cell inoculation. Tumors in all untreated control mice grew rapidly with ulceration within 51 days after tumor injection and were then sacrificed. Although a significantly longer survival could be observed in all CPT-11–treated mice as compared with untreated controls (P = 0.018), all had progressive tumor growth with ulceration within 79 days after tumor implant. Consistent with the other s.c. xenografts, animals treated with IT-101 (5 mg/kg, i.v., qwk × 3) and IT-101 (10 mg/kg, i.v., qwk × 3) had significantly longer survival than those treated with CPT-11 (P < 0.0001 and P < 0.0001, respectively) as shown in Fig. 3C. Seven of nine animals (78%) that received either IT-101 (5 mg/kg, i.v., qwk × 3) or IT-101 (10 mg/kg, i.v., qwk × 3) were pathologically confirmed tumor free and survived for at least 126 days after dosing.

**In vivo efficacy of IT-101 against disseminated human lymphoma xenograft models.** Previous studies have shown that Daudi cells and Karpas 299 cells injected i.v. into mice spread in a pattern comparable with the dissemination of human lymphomas and show preferential localization to the lymph nodes (32, 33).

We further evaluated the antilymphoma efficacy of IT-101 in disseminated Daudi tumors in which the therapy was initiated 11 days after the tumor injection. All untreated controls died of disseminated disease proceeding by progressive weight loss or were sacrificed due to being moribund within 67 days after tumor cell inoculation. In the same xenografts, 55.6% of animals receiving IT-101 (10 mg/kg, i.v., qwk × 3) and 33.3% of animals receiving IT-101 (5 mg/kg, i.v., qwk × 3) could achieve pathologic complete tumor response on day 125 posttreatment, whereas none of animals receiving CPT-11 did so (Fig. 4A). In addition, IT-101 (5 mg/kg, i.v., qwk × 3) and IT-101 (10 mg/kg, i.v., qwk × 3) could significantly prolong the survival of animals bearing disseminated Daudi* flLuc tumor when compared with CPT-11 (P = 0.0002 and P < 0.0001, respectively), as shown in Fig. 4B.

We also evaluated the efficacy of IT-101 in disseminated Karpas 299* flLuc tumor in which the therapy was initiated eight days after tumor cell injection. All untreated controls died of disseminated disease with severe weight loss or were sacrificed due to being moribund or reaching the predetermined end point of flLuc activity of >10¹⁰ p/s/cm²/sr within 29 days after tumor cell inoculation (Fig. 5A). Although all of the animals receiving therapy succumbed from disseminated disease by day 83 after tumor cell injection, animals treated with IT-101 (10 mg/kg, i.v., qwk × 3) had significantly longer survival than those treated with IT-101 (5 mg/kg, i.v., qwk × 3) and CPT-11 (P = 0.0009 and P = 0.0049, respectively) as shown in Fig. 5B.
Discussion

In order to mitigate the disadvantages of CPT, i.e. high toxicity and low clinical therapeutic efficacy, we recently attached it to a hydrophilic β-cyclodextrin-based polymer known as IT-101 (26). IT-101 maintains CPT in its active lactone form. This novel compound is too large to pass through normal vessel walls and renal clearance is inhibited. Therefore, the compound can achieve a long plasma half-life, permits a large amount of the compound to reach the tumor site through an abnormally leaky tumor vasculature, and accumulates in tumor tissue due to a lack of effective lymphatic drainage (34–36). Based on our previous study and unpublished data, the pharmacokinetics and pharmacodynamics of IT-101 at various dose levels similar to the ones explored here (0.9-9 mg/kg in rat, equivalent to 1.8-18 mg/kg scaled allometrically to mouse) were previously studied in rats (26). Area under the curve and maximum plasma concentration for both polymer-conjugated and unconjugated CPT scaled linearly with dose and were similar when normalized for the dose administered. Mean terminal half-life of conjugated CPT was 18 hours and independent of dose. These results indicate a linear dose-plasma exposure correlation for both conjugated and unconjugated CPT after administration of IT-101. In animal models, not only is the mean plasma elimination half-life for IT-101 (17-19 hours) significantly longer than that of CPT (1.3 hours), but much higher average 24-hour total CPT levels are achieved in tumors after treatment with IT-101 compared with those treated with CPT alone (26). Because CPT is an S-phase-specific drug, an optimal level of DNA Topo I inhibition is needed in which the tumors are exposed to the compound for a prolonged period of time. In addition, the lower level of freely circulating CPT may reduce the TRT (26).

Our current data clearly show the advantage of this nanoparticle technology, namely that IT-101 can provide superior antilymphoma activity than that of CPT-11 against xenografts of human lymphoma. In vitro, both IT-101 and CPT-11 caused marked inhibition of growth of three distinct human lymphoma cell lines. Because previous study has shown that the sensitivity of tumor cells to DNA Topo I-targeted cytotoxic agents is related to the level of DNA Topo I catalytic activity in the nucleus, we have chosen the three distinct s.c. lymphoma xenografts that exert a high level of DNA Topo I catalytic activity as the representatives in our study (11). Our short-term in vivo studies showed
that IT-101 was able to significantly inhibit DNA Topo I catalytic activity at 48 hours postadministration in Daudi and Karpas 299 tumors as compared with CPT-11. Such an effect results from the prolonged release kinetics of CPT from IT-101 in tumor tissue, leading to a higher degree of cytotoxicity as compared with CPT-11. This was consistent with our observation of higher levels of both IT-101 produg and free CPT observed in tumors at 24 and 48 hours postadministration compared with CPT-11 and its active metabolite SN-38. Moreover, the long-term therapeutic efficacy of IT-101 was clearly superior to CPT-11. In localized s.c. xenografts, upon discontinuation of the IT-101 treatment, most of animals attained pathologic complete tumor response at the end of the study, in agreement with the disseminated Daudi tumors treated with IT-101 (10 mg/kg, i.v., qwk × 3). Among treatment groups, IT-101 (10 mg/kg, i.v., qwk × 3) gave the best results in terms of pathologic complete tumor response and survival benefit in both s.c. and disseminated xenografts.

We also have shown that the MTD of IT-101 in SCID/NCr (BALB/c background) and NOD.scid/NCr mice bearing human lymphoma xenograft was less than that of athymic nude mice (28). This result may be explained by the fact that the SCID/NCr and NOD.scid/NCr mice are more immunocompromised as compared with athymic nude mice. Recently, a novel SN-38-incorporating polymeric micelle, NK012, has been developed (37). This compound produced a much higher cytotoxic effect against lung and colon cancer cell lines as compared with CPT-11, mainly due to an enhancement and prolonged distribution of free SN-38 in the tumor tissues. However, SN-38 is cross-resistant with the first-line chemotherapeutic agents commonly used in non-Hodgkin lymphoma such as doxorubicin and mitoxantrone (38, 39). Moreover, in a phase II study of CPT-11, a good response (complete response and partial response) was seen in only 0%, 38%, and 0% of patients with relapsed/refractory Hodgkin lymphoma, Burkitt lymphoma, and T-cell lymphoma (40). As a result, CPT-11 is not a good candidate in treating relapsed/refractory non-Hodgkin lymphoma. Therefore, the positive outcome of this study clearly shows the potential clinical benefit of IT-101 and can help in the design of treatment schedules in phase I clinical trials. IT-101 monotherapy
should be tested in patients with relapsed/refractory non-Hodgkin lymphoma. Many preclinical and clinical studies have shown that a sequential administration of a DNA Topo I inhibitor followed by a DNA Topo II inhibitor exerts a synergistic antilymphoma effect (41, 42). A recent study indicated that a single agent fluoroquinolone can inhibit both DNA Topo I and II activities in eukaryotic cells; and in combination with either CPT or etoposide, it led to a synergistic inhibition of DNA Topo I or II activity, respectively (43). As a result, it would be of value to further test an antilymphoma effect of IT-101 combined with a DNA Topo II inhibitor or fluoroquinolone. The dose-limiting toxicity of IT-101 is currently being determined in ongoing phase I clinical trial at City of Hope Comprehensive Cancer Center.

In conclusion, we have shown that IT-101 is able to control and inhibit tumor growth both in vitro and in vivo, and prolong survival of animals bearing multiple distinct human lymphoma xenografts. This preclinical therapeutic efficacy of IT-101 supports its clinical evaluation in patients with non-Hodgkin lymphoma and Hodgkin lymphoma.

Disclosure of Potential Conflicts of Interest

T. Schleur and J. Duringer are employed by x. M.E. Davis and S.J. Forman have an ownership interest in x and have served on the advisory board for x.

Acknowledgments

We thank Christopher Ruel for help with statistical analysis; City of Hope’s Animal Resource Center under the direction of Dr. Richard Ermel, Patty Wong, and, Aaron Shoop for help with animal experiments; Dr. Peiguo Chu, Dr. Karen Chang, and Sofia Loera for help with histopathologic staining and reviews; and Linling Chen for help with TOP-I catalytic activity study.

References

2. Tilly H, Gaudard P, Lepage E, et al. Primary ana-
plastic large-cell lymphoma in adults: clinical presenta-
4. Duggan DB, Petroni GR, Johnson JL, et al. Ran-
7. Velasquez WS, McLaughlin P, Tucker S, et al. ESHAP-an effective chemotherapy regime in relapsed and relapsing lymphoma: a 4-
8. Rodriguez MA, Cabanillas FC, Velasquez W, et al. Results of a salvage treatment program for relapsing lymphoma: MINE consol-
10. Hertzberg RP, Caranfa MJ, Hecht SM. On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an en-
12. Pommier Y. DNA topoisomerase I and II in cancer chemotherapy: update and pers-
14. Muggia FM, Creaven PJ, Hansen HH, Cohen MH, Selawry OS. Phase I clinical trial of weekly and daily treatment with camp-
tothecin (NSC-100880): correlation with pre-
tecan hydrochloride for the treatment of recur-
18. Saotome T, Takagi T, Sakai C, Kumagai K, Tamaru J. Combination chemotherapy with iri-
notecan and adriamycin for refractory and re-
19. Makino T, Nakahara K, Takatsuka Y, et al. [Suc-
21. Houghton PJ, Cheshire PJ, Hallman JD II, et al. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xeno-
22. Conti JA, Kemeny NE, Saltz LB, et al. Irinote-
23. Cunningham D, Pyrheron S, James RD, et al. Randomised trial of irinotecan plus sup-
24. Rougier P, Van Cutsem E, Bajetta E, et al. Ran-
26. Schleur T, Cheng J, Khin KT, Davis ME. Phar-
macokinetics and biodistribution of the camp-
27. Cheng J, Khin KT, Davis ME. Antitumor activity of B-cyclodextrin polymer-camptothecin conjuga-
30. Liu LF, Miller KG. Eukaryotic DNA topoisome-
31. Hussain I, Mohler JL, Seigler HF, Besterman JM. Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tu-
33. Tian ZG, Longo DL, Funakoshi S, et al. In vivo antitumor effects of unconjugated CD30 mono-
34. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemother-
apy: mechanism of tumor-tropic accumula-
36. Dvorak A. Perspectives in cancer research. In-
37. Koizumi F, Kitagawa M, Negishi T, et al. Novel SN-38-incorporating polymeric micelles, NK012, eradicable vascular endothelial growth factor-se-
38. Allen JD, Brinkhuis RF, Wijnholds J, Schinkel


Preclinical Results of Camptothecin-Polymer Conjugate (IT-101) in Multiple Human Lymphoma Xenograft Models

Tontanai Numbenjapon, Jianyi Wang, David Colcher, et al.


Updated version

Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/15/13/4365

Cited articles

This article cites 43 articles, 19 of which you can access for free at:
http://clincancerres.aacrjournals.org/content/15/13/4365.full.html#ref-list-1

Citing articles

This article has been cited by 5 HighWire-hosted articles. Access the articles at:
/content/15/13/4365.full.html#related-urls

E-mail alerts

Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions

To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions

To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.